Status:
COMPLETED
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
Lead Sponsor:
Pfizer
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In study A3921009, kidney t...
Eligibility Criteria
Inclusion
- Enrollment in Stage 1 of Study A3921009 and have completed 6-months of treatment with trial medications (CP-690,550 or tacrolimus)
- Recipient of a first-time kidney transplant
Exclusion
- Subject with any untreated condition that may affect drug absorption (eg, gastrectomy or clinically significant diabetic gastroenteropathy).
- Subjects who are on the waiting list for a second kidney transplant or any non-renal organ transplants.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00263328
Start Date
December 1 2005
End Date
June 1 2014
Last Update
July 13 2015
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Multi Organ Transplant Center
Los Angeles, California, United States, 90057
2
St. Vincent Medical Center
Los Angeles, California, United States, 90057
3
Transplant Research Institute
Los Angeles, California, United States, 90057
4
Stanford School of Medicine
Palo Alto, California, United States, 94304